Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 116 results for rheumatoid arthritis

  1. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or...

    Research recommendation
    Published
    15 March 2016

  2. Ultrasound in diagnosis:- What is the clinical and cost effectiveness of using ultrasound in addition to clinical assessment when there is uncertainty about the diagnosis in adults with suspected RA?

    RA. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018

  3. FRAX and QFracture in adults with secondary causes of osteoporosis:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults with secondary causes of osteoporosis?

    risk in patients with causes of secondary osteoporosis other than rheumatoid arthritis and to establish whether their effect on fracture...

    Research recommendation
    Published
    9 June 2015

  4. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  5. Management of poor prognosis:- What is the clinical and cost effectiveness of managing RA with a poor prognosis (identified as presence of anti-cyclic citrullinated peptide [CCP] antibodies or evidence of erosions on X-ray at diagnosis) with a different strategy from that used for standard management of RA?

    group. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018

  6. Ultrasound in monitoring:- What is the clinical and cost effectiveness of using ultrasound to monitor disease in adults with RA when clinical examination is inconclusive or inconsistent with other signs of disease activity?

    accurately. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018

  7. Short-term bridging treatment with glucocorticoids:- What is the clinical and cost effectiveness of short-term bridging treatment with glucocorticoids for adults with RA starting a new disease-modifying anti-rheumatic drug (DMARD), including the most effective dosing strategy and mode of administration?

    treatment. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

    Research recommendation
    Published
    11 December 2018

  8. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 October 2014

  9. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015

  10. Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    4 January 2023
    View recommendations

    Sections for TA856

  11. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    23 July 2025
    View quality statements

    Sections for QS100

  12. Osteoarthritis in over 16s: diagnosis and management (NG226)

    This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.

    NICE guideline
    Published
    19 October 2022
    View recommendations

    Sections for NG226

  13. Osteoarthritis in over 16s (QS87)

    This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    19 October 2022
    View quality statements

    Sections for QS87

  14. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA920

  15. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

    Technology appraisal guidance
    Last updated
    7 February 2018
    View recommendations

    Sections for TA161